The Arizona Cancer Center will conduct biologic assays
to screen TRAP-generated compounds for pharmacologic activity against cancer-related drug targets.
Genmab will use its fully human antibody technology in combination with its broad antibody development capabilities, including a diverse array of biologic assays
and animal disease models, to generate and test fully human antibodies to these novel disease targets.
of Baystate Medical Center, a surgical pathologist who maintains an active research interest in tissue-based immunohistochemical and molecular biologic assays
for cancer diagnosis; and Shirin Nash, M.